home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

62.37 -0.43 (-0.68%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

47 48 Next >

Dexcom Reports First Quarter 2024 Financial Results

April 25, 2024

From DexCom, Inc.

Via Business Wire

Staar Surgical Stock Climbs The Leadership Ladder With Jump To 84 RS Rating ↗

April 25, 2024

On Thursday, implantable lens maker Staar Surgical stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier.

Via Investor's Business Daily

3 Innovative Stocks to Buy Before Earnings Amid the Market Pullback ↗

April 20, 2024

Today’s episode of Full Court Finance at Zacks dives into the recent stock market pullback. We then turn our attention to three innovators in their respective industries—Vertiv, Align Technology, and...

Via Talk Markets

How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher ↗

April 18, 2024

ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use.

Via Investor's Business Daily

$1000 Invested In DexCom 5 Years Ago Would Be Worth This Much Today ↗

April 17, 2024

Via Benzinga

Why NASDAQ:DXCM Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

April 11, 2024

Via Chartmill

The Analyst Verdict: DexCom In The Eyes Of 4 Experts ↗

April 10, 2024

Via Benzinga

DexCom Inc Chart Analysis ↗

March 26, 2024

Technical analysis of the stock chart for DXCM.

Via Talk Markets

Here's How Much $1000 Invested In DexCom 15 Years Ago Would Be Worth Today ↗

March 25, 2024

Via Benzinga

3 Weight-Loss ETFs to Profit From the Obesity Drug Boom ↗

April 17, 2024

Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment.

Via InvestorPlace

Topics ETFs

Disruptive Forces: 3 Game-changing Stocks Reshaping the Tech Landscape ↗

April 13, 2024

This April, discover three game-changing tech stocks with disruptive technologies poised to future-proof your portfolio in 2024.

Via InvestorPlace

Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit ↗

April 12, 2024

Continuous glucose monitors have spiked in popularity since the advent of weight-loss drugs. Is chronic disease at its end?

Via Investor's Business Daily

Nasdaq Nightmares: 3 Stocks to Sell Before Reality Sets In ↗

April 10, 2024

DoorDash, DexCom, and Advanced Micro Devices are three Nasdaq stocks to sell before reality sets in as exuberance may be fading.

Via InvestorPlace

3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild ↗

April 10, 2024

Discover top obesity drug stocks set to soar as demand surges. Eli Lilly, Novo Nordisk, & Dexcom lead with revolutionary treatments

Via InvestorPlace

NASDAQ:DXCM—Positioned as a High-Growth Stock, Ready for a Potential Breakout. ↗

March 21, 2024

DEXCOM INC (NASDAQ:DXCM) qualifies as a high growth stock and is consolidating.

Via Chartmill

DexCom's Options: A Look at What the Big Money is Thinking ↗

March 20, 2024

Via Benzinga

DexCom Stock Sees IBD Stock Market Rating Sweetens Ups; Earns 83 RS Rating ↗

April 08, 2024

The Relative Strength (RS) Rating for DexCom stock entered a new percentile Monday, with a rise from 80 to 83.

Via Investor's Business Daily

2 Growth Stocks to Buy Hand Over Fist in April ↗

April 08, 2024

These healthcare companies' target markets substantially overlap.

Via The Motley Fool

7 Nasdaq Stocks to Sell in April Before They Crash & Burn ↗

April 03, 2024

The momentum in growth companies is likely to run out. Move on from these Nasdaq stocks to sell in April before it's too late.

Via InvestorPlace

Dexcom Publishes Annual Sustainability Report

April 03, 2024

From DexCom, Inc.

Via Business Wire

Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time

April 02, 2024

From DexCom, Inc.

Via Business Wire

DexCom Stock Gains from GLP-1 Diabetic Users

April 02, 2024

DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People

Via MarketBeat

3 Overvalued S&P 500 Stocks for Your ‘Do NOT Buy’ List ↗

April 01, 2024

The S&P 500’s current P/E ratio is 30% higher than a year ago, making it easier to find overvalued S&P 500 stocks to buy.

Via InvestorPlace

Topics Stocks

Micron, Dropbox And 2 Other Stocks Insiders Are Selling ↗

April 01, 2024

The Nasdaq 100 closed lower by around 0.1% on Thursday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Market Cap Game Show: Andy Cross vs. Bill Mann ↗

March 30, 2024

Join the "Rule Breaker Investing" fun.

Via The Motley Fool

Dexcom Stock Shows Market Leadership, Gets Rating Upgrade. Prognosis Good. ↗

March 26, 2024

Among its other key ratings Dexcom has a near-best 98 Earnings Per Share Rating out of 99, reflecting strong profit growth this past year.

Via Investor's Business Daily

Two Hot AI Stocks Lead S&P 500 Monday ↗

March 25, 2024

Super Micro and Micron , two big winners in 2024, led the way Monday.

Via Investor's Business Daily

Topics Artificial Intelligence Stocks

More Than 86% of Analysts Who Cover These 3 Stocks Rate Them a ‘Buy’ ↗

March 25, 2024

Investors should take notice of these stocks with high analyst ratings. It's time to load up your portfolio.

Via InvestorPlace

S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind ↗

March 23, 2024

DexCom, Blackstone and Royal Caribbean head this list of five stocks.

Via Investor's Business Daily

Topics Economy Stocks

Edwards Lifesciences Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark ↗

March 19, 2024

The Relative Strength (RS) Rating for Edwards Lifesciences stock jumped into a new percentile Tuesday, with a rise from 78 to 81.

Via Investor's Business Daily

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

47 48 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com